Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 21.8% in the 4th quarter, HoldingsChannel reports. The firm owned 1,248,721 shares of the company’s stock after purchasing an additional 223,384 shares during the period. Pictet Asset Management Holding SA’s holdings in Viridian Therapeutics were worth $23,938,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VRDN. R Squared Ltd acquired a new position in shares of Viridian Therapeutics in the fourth quarter valued at approximately $26,000. AlphaQuest LLC grew its holdings in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Viridian Therapeutics during the third quarter worth approximately $149,000. Quantbot Technologies LP purchased a new position in shares of Viridian Therapeutics in the 4th quarter worth $164,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Viridian Therapeutics in the 3rd quarter worth about $208,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on VRDN shares. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Monday, December 16th. Royal Bank of Canada lifted their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Trading Down 6.6 %

NASDAQ:VRDN opened at $13.48 on Tuesday. The company has a market cap of $1.10 billion, a PE ratio of -3.13 and a beta of 1.05. The business’s 50 day moving average is $16.66 and its two-hundred day moving average is $19.66. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.